drugset / Trial / NCT01629563

PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata

NCT01629563

Phase 3 Completed 451 enrolled PregLem SA
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase III, multicentre, randomized, double-blind, parallel group, long-term study investigating the efficacy and safety of the 5mg and 10mg doses of PGL4001 for the treatment of uterine myoma.

Timeline

Start
2012-06
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ulipristal Acetate Unknown 5 mg Oral
Subject Ulipristal Acetate Unknown 10 mg Oral

Indications